153 related articles for article (PubMed ID: 16797207)
1. Immunogenicity of a recombinant protein containing the Plasmodium vivax vaccine candidate MSP1(19) and two human CD4+ T-cell epitopes administered to non-human primates (Callithrix jacchus jacchus).
Rosa DS; Iwai LK; Tzelepis F; Bargieri DY; Medeiros MA; Soares IS; Sidney J; Sette A; Kalil J; Mello LE; Cunha-Neto E; Rodrigues MM
Microbes Infect; 2006 Jul; 8(8):2130-7. PubMed ID: 16797207
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the immunogenic properties of recombinant proteins representing the Plasmodium vivax vaccine candidate MSP1(19) expressed in distinct bacterial vectors.
Cunha MG; Rodrigues MM; Soares IS
Vaccine; 2001 Nov; 20(3-4):385-96. PubMed ID: 11672901
[TBL] [Abstract][Full Text] [Related]
3. Immunogenic properties of the Plasmodium vivax vaccine candidate MSP1(19) expressed as a secreted non-glycosylated polypeptide from Pichia pastoris.
Soares IS; Rodrigues MM
Parasitology; 2002 Mar; 124(Pt 3):237-46. PubMed ID: 11922426
[TBL] [Abstract][Full Text] [Related]
4. The pan HLA DR-binding epitope improves adjuvant-assisted immunization with a recombinant protein containing a malaria vaccine candidate.
Rosa DS; Tzelepis F; Cunha MG; Soares IS; Rodrigues MM
Immunol Lett; 2004 Apr; 92(3):259-68. PubMed ID: 15081621
[TBL] [Abstract][Full Text] [Related]
5. Immunogenic properties of a recombinant fusion protein containing the C-terminal 19 kDa of Plasmodium falciparum merozoite surface protein-1 and the innate immunity agonist FliC flagellin of Salmonella typhimurium.
Bargieri DY; Leite JA; Lopes SC; Sbrogio-Almeida ME; Braga CJ; Ferreira LC; Soares IS; Costa FT; Rodrigues MM
Vaccine; 2010 Apr; 28(16):2818-26. PubMed ID: 20170765
[TBL] [Abstract][Full Text] [Related]
6. New malaria vaccine candidates based on the Plasmodium vivax Merozoite Surface Protein-1 and the TLR-5 agonist Salmonella Typhimurium FliC flagellin.
Bargieri DY; Rosa DS; Braga CJ; Carvalho BO; Costa FT; Espíndola NM; Vaz AJ; Soares IS; Ferreira LC; Rodrigues MM
Vaccine; 2008 Nov; 26(48):6132-42. PubMed ID: 18804504
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant requirement for successful immunization with recombinant derivatives of Plasmodium vivax merozoite surface protein-1 delivered via the intranasal route.
Bargieri DY; Rosa DS; Lasaro MA; Ferreira LC; Soares IS; Rodrigues MM
Mem Inst Oswaldo Cruz; 2007 Jun; 102(3):313-7. PubMed ID: 17568936
[TBL] [Abstract][Full Text] [Related]
8. A chimeric protein-based malaria vaccine candidate induces robust T cell responses against Plasmodium vivax MSP1
Fonseca JA; Cabrera-Mora M; Singh B; Oliveira-Ferreira J; da Costa Lima-Junior J; Calvo-Calle JM; Lozano JM; Moreno A
Sci Rep; 2016 Oct; 6():34527. PubMed ID: 27708348
[TBL] [Abstract][Full Text] [Related]
9. Potent immunogenic short linear peptide constructs composed of B cell epitopes and Pan DR T helper epitopes (PADRE) for antibody responses in vivo.
del Guercio MF; Alexander J; Kubo RT; Arrhenius T; Maewal A; Appella E; Hoffman SL; Jones T; Valmori D; Sakaguchi K; Grey HM; Sette A
Vaccine; 1997 Mar; 15(4):441-8. PubMed ID: 9141216
[TBL] [Abstract][Full Text] [Related]
10. A recombinant vaccine based on domain II of Plasmodium vivax Apical Membrane Antigen 1 induces high antibody titres in mice.
Gentil F; Bargieri DY; Leite JA; Françoso KS; Patricio MB; Espíndola NM; Vaz AJ; Palatnik-de-Sousa CB; Rodrigues MM; Costa FT; Soares IS
Vaccine; 2010 Aug; 28(38):6183-90. PubMed ID: 20654667
[TBL] [Abstract][Full Text] [Related]
11. Long-lasting protective immune response to the 19-kilodalton carboxy-terminal fragment of Plasmodium yoelii merozoite surface protein 1 in mice.
Jeamwattanalert P; Mahakunkijcharoen Y; Kittigul L; Mahannop P; Pichyangkul S; Hirunpetcharat C
Clin Vaccine Immunol; 2007 Apr; 14(4):342-7. PubMed ID: 17314232
[TBL] [Abstract][Full Text] [Related]
12. Generation, characterization and immunogenicity of a novel chimeric recombinant protein based on Plasmodium vivax AMA-1 and MSP1
Rocha MV; Françoso KS; Lima LC; Camargo TM; Machado RLD; Costa FTM; Rénia L; Nosten F; Russell B; Rodrigues MM; Soares IS
Vaccine; 2017 Apr; 35(18):2463-2472. PubMed ID: 28341111
[TBL] [Abstract][Full Text] [Related]
13. CpG oligodeoxynucleotide enhances immunity against blood-stage malaria infection in mice parenterally immunized with a yeast-expressed 19 kDa carboxyl-terminal fragment of Plasmodium yoelii merozoite surface protein-1 (MSP1(19)) formulated in oil-based Montanides.
Hirunpetcharat C; Wipasa J; Sakkhachornphop S; Nitkumhan T; Zheng YZ; Pichyangkul S; Krieg AM; Walsh DS; Heppner DG; Good MF
Vaccine; 2003 Jun; 21(21-22):2923-32. PubMed ID: 12798636
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of immune responses to a Plasmodium vivax CSP-based recombinant protein vaccine candidate in combination with second-generation adjuvants in mice.
Lumsden JM; Nurmukhambetova S; Klein JH; Sattabongkot J; Bennett JW; Bertholet S; Fox CB; Reed SG; Ockenhouse CF; Howard RF; Polhemus ME; Yadava A
Vaccine; 2012 May; 30(22):3311-9. PubMed ID: 22425788
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the immune responses induced by soluble and particulate Plasmodium vivax circumsporozoite vaccine candidates formulated in AS01 in rhesus macaques.
Vanloubbeeck Y; Pichyangkul S; Bayat B; Yongvanitchit K; Bennett JW; Sattabongkot J; Schaecher K; Ockenhouse CF; Cohen J; Yadava A;
Vaccine; 2013 Dec; 31(52):6216-24. PubMed ID: 24144477
[TBL] [Abstract][Full Text] [Related]
16. Expression of disulphide-bridge-dependent conformational epitopes and immunogenicity of the carboxy-terminal 19 kDa domain of Plasmodium yoelii merozoite surface protein-1 in live attenuated Salmonella vaccine strains.
Somner EA; Ogun SA; Sinha KA; Spencer Valero LM; Lee JJ; Harrison JA; Holder AA; Hormaeche CE; Khan ACM
Microbiology (Reading); 1999 Jan; 145 ( Pt 1)():221-229. PubMed ID: 10206702
[TBL] [Abstract][Full Text] [Related]
17. Genetic linkage of autologous T cell epitopes in a chimeric recombinant construct improves anti-parasite and anti-disease protective effect of a malaria vaccine candidate.
Singh B; Cabrera-Mora M; Jiang J; Galinski M; Moreno A
Vaccine; 2010 Mar; 28(14):2580-92. PubMed ID: 20097151
[TBL] [Abstract][Full Text] [Related]
18. Partial protection against Plasmodium vivax blood-stage infection in Saimiri monkeys by immunization with a recombinant C-terminal fragment of merozoite surface protein 1 in block copolymer adjuvant.
Yang C; Collins WE; Sullivan JS; Kaslow DC; Xiao L; Lal AA
Infect Immun; 1999 Jan; 67(1):342-9. PubMed ID: 9864235
[TBL] [Abstract][Full Text] [Related]
19. Development of experimental carbohydrate-conjugate vaccines composed of Streptococcus pneumoniae capsular polysaccharides and the universal helper T-lymphocyte epitope (PADRE).
Alexander J; del Guercio MF; Frame B; Maewal A; Sette A; Nahm MH; Newman MJ
Vaccine; 2004 Jun; 22(19):2362-7. PubMed ID: 15193395
[TBL] [Abstract][Full Text] [Related]
20. Recombinant Mycobacterium bovis bacillus Calmette-Guérin secreting merozoite surface protein 1 (MSP1) induces protection against rodent malaria parasite infection depending on MSP1-stimulated interferon gamma and parasite-specific antibodies.
Matsumoto S; Yukitake H; Kanbara H; Yamada T
J Exp Med; 1998 Sep; 188(5):845-54. PubMed ID: 9730886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
